DGAP-Adhoc: Dermapharm Holding SE expects the cooperation with BioNTech SE in vaccine production to make a high double-digit million € contribution to sales in 2021

2021. február 12., péntek, 13:05





DGAP-Ad-hoc: Dermapharm Holding SE / Key word(s): Development of Sales


Dermapharm Holding SE expects the cooperation with BioNTech SE in vaccine production to make a high double-digit million € contribution to sales in 2021


12-Feb-2021 / 13:05 CET/CEST


Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.


The issuer is solely responsible for the content of this announcement.




Disclosure of Insider Information pursuant to Section 17 (1) 1 of the Regulation (EU)
No. 596/2014 on Market Abuse, as amended
(Market Abuse Regulation - MAR)



Dermapharm Holding SE expects the cooperation with BioNTech SE in vaccine production to make a high double-digit million € contribution to sales in 2021



Grünwald, February 12, 2021 - Dermapharm Holding SE (WKN: A2GS5D, ISIN: DE000A2GS5D8) expects the cooperation with BioNTech SE, Mainz, in the production of the Covid-19 vaccine Comirnaty(R) to contribute a high double-digit million € amount to the consolidated sales of the Dermapharm Group in the full year 2021. This is the result of a current plan for vaccine production approved today by the Management Board of Dermapharm Holding SE. Among other things, it includes the establishment of additional production capacities at the Reinbek site, which are scheduled to go into operation in May 2021.



>End of the ad hoc announcement<


Contacts





Investor Relations &

Corporate Communications

Britta Hamberger

Phone: +49 (0)89 - 64186-233

Fax: +49 (0)89 - 64186-165

e-Mail: ir@dermapharm.com
cometis AG

Claudius Krause

Phone: +49 (0)611 - 205855-28

Fax: +49 (0)611 - 205855-66

e-Mail: ir@dermapharm.com

 

 



 











12-Feb-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



























Language: English
Company: Dermapharm Holding SE

Lil-Dagover-Ring 7

82031 Grünwald

Germany
Phone: +49 (0)89 64 86-0
E-mail: ir@dermapharm.com
Internet: ir.dermapharm.de
ISIN: DE000A2GS5D8
WKN: A2GS5D
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Stuttgart, Tradegate Exchange
EQS News ID: 1167965





 
End of Announcement DGAP News Service




1167965  12-Feb-2021 CET/CEST







fncls.ssp?fn=show_t_gif&application_id=1167965&application_name=news&site_id=geo_holding_tug
Tilos a hír bármilyen adatbázisba történő mentése vagy annak továbbítása harmadik fél számára;kereskedelmi viszonylatban vagy kereskedelmi céllal csak a Deutsche Gesellschaft für Ad-hoc-Publizität mbh írásos engedélyével történhet.

Közzétételek - archívum